目的：探讨过敏性鼻炎口服液治疗常年性变态反应性鼻炎（PAR）的机制。
Purpose:To study the mechanism of the treatment of perennial allergic rhinitis(PAR) with Allergic Rhinitis Oral Liquid(AROL).
对558名2 ~ 11岁常年性变态反应性鼻炎患儿进行另一项研究，以安慰剂组为对照，比较氟替卡松安特酰胺鼻腔喷雾110mcg和55mcg长期治疗的效果。
Another study compared the effects of long-term treatment with FFNS at 110 MCG and 55 MCG, versus placebo, of year-round allergies in 558 children ages 2 through 11.
应用推荐